Find us on:

Research

Disease
Research Type
Reported as
Publication Type
Sort By
Total: 132
The Uses of Naltrexone in Dermatological Conditions
Research Type Human Reported as Review Date December 21, 2018 Authors B. Lee, D. Elston Institution Baylor College of Medicine; Medical University of South Carolina Disease Acantholytic, Alopecia, Darie, Hailey-Hailey, Lichen Planopilaris, Pruritus, Psoriasis
BACKGROUND: Naltrexone in standard and reduced doses is efficacious in many inflammatory and acantholytic disorders. OBJECTIVE: We summarized current data of naltrexone relevant to dermatological practice. METHODS: An English language PubMed literature search was performed using the terms naltrexone, low-dose naltrexone, Hailey-Hailey, psoriasis, lichen planopilaris, alopecia, opioid, opioid receptor, treatment, dermatology, monitoring, side effect, skin, pruritus, cutaneous, acantholytic, and...
Intermittent blockade of OGFr and treatment of autoimmune disorders
Research Type Human Animal Reported as Review Date December 12, 2018 Authors IS Zagon, PJ McLaughlin PJ Institution Penn State University Disease AutoImmune (general), Crohn's Disease, Fibromyalgia, MS (Multiple Sclerosis)
This mini-review presents information on the intermittent blockade of the opioid growth factor (OGF)-OGF receptor (OGFr) axis by low-dose naltrexone (LDN), and the role of enkephalin (i.e. OGF) in autoimmune disorders, specifically multiple sclerosis, Crohn's, and fibromyalgia. Clinical reports on subjects taking LDN have documented reduced fatigue, few side-effects, and improved overall health. Preclinical studies on mice with experimental autoimmune encephalomyelitis (EAE), the animal model of...
Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review
Research Type Human Reported as Review Date November 28, 2018 Authors " C. Ekelem, M. Juhasz, P. Khera, N.A. Mesinkovska NA" Institution University of California, Irvine, Howard University Hospital Disease Chronic Inflammatory Skin Disease, Hailey-Hailey, Lichen Planopilaris, Lichen Sclerosus, Psoriasis, Systemic Sclerosis
IMPORTANCE: Dermatology is encountering increasing rates of autoimmune disease manifesting in primary skin conditions that are difficult to treat without a risk of immunosuppression. Naltrexone is an orally active opioid antagonist that influences a variety of systemic pathways, including the immune system, in low doses of 1.5 to 4.0 mg/d. This phenomenon has piqued the interest of researchers and practitioners in regard to low-dose naltrexone's potential in the treatment of several autoimmune c...
The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma
Research Type Animal Reported as Clinical Trial Date October 04, 2018 Authors Machado MC, da Costa-Neto JM, Portela RD, D'Assis MJMH, Martins-Filho OA, Barrouin-Melo SM, Borges NF, Silva FL, Estrela-Lima A. Institution Federal University of Bahi (Brazil), Federal University of Recôncavo da Bahia (Brazil), René Rachou Research Center, Estadual University of Santa Cruz (Brazil) Disease Cancer (general)
The objective of this study was to evaluate the effect of low-dose naltrexone (LDN) as a carboplatin chemotherapy-associated drug in female dogs with mammary carcinoma in benign mixed tumors (MC-BMT) after mastectomy and to assess its association with quality of life and survival rates. Sixty female dogs were included in this study, all of which had histopathological diagnosis of MC-BMT and were divided into three groups: G1 (control), consisting of animals submitted only to mastectomy with or w...
Successful treatment of dermatomyositis with low-dose naltrexone
Research Type Human Reported as Case Report/Series/Restrospective Study Date September 24, 2018 Authors Thanh Tran, Alessandra Chen, Scott Worswick Institution UCLA Disease Dermatomyositis
Low-dose naltrexone has been shown to treat autoimmune conditions, such as multiple sclerosis, fibromyalgia, and Crohn's disease. We present two cases in which low-dose naltrexone proved an effective therapy for dermatomyositis (DM), an idiopathic inflammatory myopathy. A search of PubMed for “low dose naltrexone” and “dermatomyositis” did not reveal any reported cases of the use of low-dose naltrexone in DM. We suspect that low-dose naltrexone produces an antiinflammatory effect via inh...
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization
Research Type Human Reported as Review Date September 21, 2018 Authors Karlo Toljan, Bruce Vrooman Institution University of Zagreb; Dartmouth-Hitchcock Medical Center; Geisel School of Medicine at Dartmouth
Naltrexone and naloxone are classical opioid antagonists. In substantially lower than standard doses, they exert different pharmacodynamics. Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signaling in addition to systemically upregulating endogenous opioid signaling by transient opioid-receptor blockade. Clinical reports of LDN have demonstrated possible benefits in diseases such as fibro...
Treatment of psoriasis vulgaris using low-dose naltrexone
Research Type Human Reported as Case Report/Series/Restrospective Study Date September 18, 2018 Authors Alanna C. Bridgman and Mark G. Kirchhof Institution Queen's University, University of Ottawa, The Ottawa Hospital Disease Psoriasis
A 60-year-old white woman presented with a history of moderate, generalized plaque psoriasis covering 10% of her body surface area (BSA). The patient began low-dose naltrexone, 4.5 mg daily. The patient's psoriatic lesions were significantly improved at 3 months, and the affected BSA had decreased from 10% to 1% after 6 months of treatment. The calculated PASI (psoriasis area severity index) score decreased from 7.2 to 0.9 after 6 months of treatment. Symptoms of pruritus also improved with nal...
Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone
Research Type Human Reported as Case Report/Series/Restrospective Study Date August 01, 2018 Authors Natalie Kollman and Jonathan Blass Institution Case Western Reserve University School of Medicine Disease Hailey-Hailey
Hailey-Hailey disease, otherwise known as familial benign chronic pemphigus, is a genetic intraepidermal blistering disorder. In nongeneralized HHD, there have been a few published case reports of HHD treated successfully with low-dose naltrexone (LDN). The exact mechanism by which naltrexone works for HHD is unclear. The phenotypic expression of HHD can be quite variable. Although at times minimal, in rare cases, this disorder cannot only become generalized but result in systemic sequelae due...
Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Research Type Human Reported as Case Report/Series/Restrospective Study Date July 15, 2018 Authors George Muller, Robert Grieshaber, Floyd Talley, Mike Riepl, Don Fellows Institution Compounding Business Services; Grieshaber Dermatology; Floyd's Family Pharmacy; Gateway Pharmacy Disease Psoriasis
The ancient autoimmune skin condition psoriasis is still ubiquitous worldwide, produces the same, often-intolerable effects noted in its earliest recorded descriptions, and remains without cure. Management options designed to resolve the itchy, scaly, weeping, erythematous, and often widespread lesions of that disorder are now available, but they vary in efficacy, most are associated with the development of severe adverse effects, and many are prohibitively expensive. In this article, we describ...
Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
Research Type Human Reported as Case Report/Series/Restrospective Study Date July 05, 2018 Authors J.A. Miskoff, M. Chaudhri Institution Jersey Shore University Medical Center Disease Cancer (general), Lung Cancer
Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Additionally, clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors including non-small cell lung cancer (NSCLC) at the cellular level by augmenting the immune system. We presen...